Exopolysaccharide from Lactobacillus rhamnosus ZFM231 alleviates DSS-induced colitis in mice by regulating gut microbiota.
- 2022-07-02
- Clinical Trial
- Journal of the Science of Food and Agriculture 102(15)
- C. Wan
- Wen-Wen Qian
- W. Liu
- X. Pi
- Meng Tang
- Xiao-Lin Wang
- Q. Gu
- Ping Li
- Tao Zhou
- PubMed: 35707876
- DOI: 10.1002/jsfa.12070
14 Insights on
- Improved Gut Microbiota Diversity
- Reduced Tumor Necrosis Factor Alpha
- Increased Short-Chain Fatty Acid Levels
- Reduced Body Weight
- Reduced Tissue Damage from Colitis
- Reduced Inflammation Levels
- Improved Colonic Length
- Improved Disease Activity Index Score
- Increased Short-Chain Fatty Acid Production
- Improved Colonic Health
- Reduced Disease Activity Score
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Body Weight Loss
- Restored Microbial Diversity
- Low evidence
- Rigorous Journal
- Animal Study